Question 1

Accepted Answer

The company’s registered office is situated at Else-Kröner-Str. 1, 61352 Bad Homburg v.d.H., Germany.

Question 2

Accepted Answer

The origins of Fresenius SE & Co. KGaA date back to the firm “Dr. Eduard Fresenius, Chemisch-pharmazeutische Industrie”, which was founded in 1912 by Dr. Eduard Fresenius, the proprietor of the Hirsch pharmacy in Frankfurt am Main. The founder’s wide-ranging contacts to doctors and scientists served as the foundations for the company and shaped its extensive portfolio of products. The company was converted into the joint stock company Fresenius AG at the end of 1981 in order to secure its continuity. The conversion of Fresenius SE into a partnership limited by shares (KGaA) took effect on January 28, 2011 with the entry of Fresenius SE & Co. KGaA in the commercial register of Bad Homburg municipal court.

Question 3

Accepted Answer

Fresenius is a global healthcare group. For more than 100 years, we have been combining cutting-edge technology with a focus on patients, paving the way for the therapies of the future. We save and improve lives and health. We provide access to affordable and innovative medical products and clinical care of the highest quality.

The Fresenius Group comprises the Operating Companies Fresenius Kabi and Fresenius Helios as well as the Investment Company Fresenius Medical Care. Each business segment is market leader in a major growth area of healthcare. In May 2024, Fresenius announced a structured exit from the Investment Company Vamed and completes the strategic portfolio restructuring as part of #FutureFresenius. As of Q2 2024, Vamed is no longer a reporting segment of Fresenius.

Fresenius has successfully completed the deconsolidation of Fresenius Medical Care: The change in legal form was entered in the commercial register on November 30, 2023.

Question 4

Accepted Answer

The Group has 178,394 employees as of December 2025 (December 31, 2024: 176,486).

Question 5

Accepted Answer

The financial year ends on December 31.

Question 6

Accepted Answer

Fresenius SE & Co. KGaA ("Fresenius") reports since January 1, 2017 in accordance with International Financial Reporting Standards (IFRS).

Fresenius, as a publicly traded company based in a European Union member country, is required to prepare and publish its consolidated financial statements in accordance with International Financial Reporting Standards (IFRS) pursuant to Section 315e of the German Commercial Code (HGB).

Question 7

Accepted Answer

The Group had total assets of €41,395 million as of December 31, 2025 (December 31, 2024: €43,550 million) while shareholders’ equity including minority interests amounted to €19,767 million (December 31, 2024: €20,290 million).

Question 8

Accepted Answer

Revenue of €22,554 million was achieved in the financial year 2025 (December 31, 2024: €21,526).

Question 9

Accepted Answer

For an overview of analysts’ current recommendation please click here.

Question 10

Accepted Answer

For an overview of our next earnings releases please click here.

Question 11

Accepted Answer

In the Fresenius Financial Framework, organic revenue growth represents the key performance indicator for the Group’s growth and that of the business segments. With the Fresenius Financial Framework, we have defined annual organic revenue growth ranges (ambition levels) for the operating companies. No annual ambition levels were defined for organic sales growth of the investment companies.

As part of the Fresenius financial framework, we have defined annual margin bands (ambition levels) for the business segments. These serve as an ambition level for the internal management of our business sectors and are benchmarked against leading competitors. The annual EBIT margin is defined as earnings before interest and taxes divided by revenue. To improve comparability of operating performance over several periods, the earnings figure is adjusted for special items where necessary.

At Group level, we primarily use earnings before interest and taxes (EBIT) and EBIT growth in constant currency. To improve comparability of operating performance over several periods, the earnings figure is adjusted for special items where necessary.

For an overview of our performance measures please click here.

Question 12

Accepted Answer

The Fresenius preference shares were admitted to trading in December 1986. The Fresenius ordinary shares were admitted to trading in July 1992. The shares were listed on the stock exchanges in Frankfurt, Düsseldorf and Munich. In January 2011, the legal form of Fresenius SE was changed to a partnership limited by shares (KGaA) and all preference shares were mandatorily converted into ordinary shares.

Question 13

Accepted Answer

The Bloomberg symbol of the Fresenius SE ordinary share on XETRA is FRE GR. The Reuters symbol on XETRA is FREG.de.

Question 14

Accepted Answer

As part of the full year reporting in February 2025, Fresenius defined a new dividend policy designed to ensure attractive shareholder returns while maintaining strategic flexibility. Going forward, Fresenius will pay out 30 to 40% of its Group core net income excluding Fresenius Medical Care and before special items as dividend.

At the 2025 Annual General Meeting, Fresenius approved a dividend of € 1.00 per share for the 2024 financial year. The dividend represents a significant increase compared to the 2022 base and demonstrates Fresenius’ improving financial strength and its commitment to delivering shareholder value.

Question 15

Accepted Answer

The dividend for the 2024 financial year amounts to €1.00 per share.

The total distribution to the shareholders of Fresenius SE & Co. KGaA amounts to €563 million, which corresponds to 32% of the Group’s net income before special items. Based on this dividend proposal and the year-end share price, the dividend yield amounts to 3.0%.

The dividend was paid on May 28, 2025.

For fiscal year 2025, Fresenius will propose to the Annual General Meeting a dividend of €1.05 per share, an increase of 5% compared with the previous year. The payout ratio is 37%.

Further information on the dividend policy of Fresenius SE & Co. KGaA can be found https://www.fresenius.com/dividends.

Question 16

Accepted Answer

German shares must be deposited no later than the day of the Annual General Meeting in order for shareholders to be entitled to a dividend. The dividend will be paid automatically to your account by your bank/saving bank.

Question 17

Accepted Answer

The subscribed capital of Fresenius SE & Co. KGaA amounted to 563,237,277 ordinary shares as of December 31, 2025 (December 31, 2024: 563,237,277). The shares of Fresenius SE & Co. KGaA are non-par-value bearer shares. Each share represents € 1.00 of the capital stock.

Question 18

Accepted Answer

The Else Kröner-Fresenius-Stiftung is the largest shareholder of Fresenius SE & Co. KGaA, holding approximately 27% of the voting capital. An overview of our shareholder structure can be found here.

Question 19

Accepted Answer

Under "Share Price" you can find our interactive tool that allows you to analyze and graph the Fresenius SE & Co. KGaA share price.

Question 20

Accepted Answer

Under "Outlook" you can find the outlook for the Fresenius Group and each of the business segments.

Question 21

Accepted Answer

Our Annual General Meeting (AGM) of Fresenius SE & Co. KGaA took place on May 23, 2025, at the Congress Center, Messe Frankfurt, Ludwig-Erhard-Anlage 1, 60327 Frankfurt am Main, Germany.

The next Annual General Meeting is scheduled to take place on 22 May 2026.

Question 22

Accepted Answer

The record date for the 2025 Annual General Meeting was May 1, 2025. In order to participate in the Annual General Meeting and to exercise voting rights shareholders have to submit special proof of share ownership which refers to the beginning of the record date, i.e. 24.00 h CEST.

The record date does not result in a blocking period during which it is not allowed to sell shares. Even in the event of full or partial disposal of the shareholding following the record date, only the shares owned by the shareholder on the record date will be relevant for participation in the Annual General Meeting and the scope of voting rights, i.e. disposal of shares after the record date will not affect entitlement to participate in the Annual General Meeting and the scope of voting rights. This also applies if (additional) shares are purchased after the record date. Persons who do not own any shares on the record date, and become shareholders only after the record date, are not entitled to participate in the Annual General Meeting and to exercise voting rights.

Question 23

Accepted Answer

All shareholders were able to follow the Annual General Meeting online or appoint a representative as long as he/she fulfils the conditions stated in the agenda. However, only holders of ordinary shares have a voting right as a general rule. You can enter the agenda on our website as from the day of its publication.

Question 24

Accepted Answer

The invitation with the agenda of the Annual General Meeting will be delivered to you by your depositary bank before the Annual General Meeting. Enclosed with the invitation is a letter from your depositary bank with which you can order the admission ticket either for yourself or for someone else of your choice.

Question 25

Accepted Answer

Of course you can receive a free copy of the documents regarding the Annual General Meeting. Please contact our Investor Relations department.

Question 26

Accepted Answer

Sustainability is part of our corporate strategy and anchored in our operational business.

Our mission is to save and improve human lives. We are “Committed to Life”. We focus on opportunities that arise from sustainable business practices and use them to drive measurable progress. This approach is built on a unique corporate legacy that spans more than a century. We are guided by strong principles and a clear direction for the future.

Our Sustainability Framework guides our daily actions and shapes how we integrate sustainability into our business.

We focus on three core dimensions:
➔ Human Dimension
➔ Planet Dimension
➔ Ethical Foundation

For a detailed overview of our approach to sustainability, our focus topics and related goals please refer to the Sustainability section on our website and to our Annual Report 2025.

Question 27

Accepted Answer

The Group-wide topic of sustainability, related impacts, risks and opportunities, are anchored in the Management Board member responsible for Legal, Compliance, Risk Management, Sustainability, Human Resources, Corporate Audit and transformation of the Vamed businesses (Management Board member Sustainability).

The Group Sustainability function acts as a center of expertise for all sustainability aspects within the Group. The function monitors regulatory developments, identifies material topics, and develops priorities and potential for implementing the sustainability strategy. The Group function supports its Group-wide implementation and reviews progress as part of the annual reporting. Furthermore, there are repeated exchanges with all Group functions and the sustainability officers of the operating companies during the course of the year in order to take into account the respective business models and discuss the feasibility of measures. In addition, the Group Sustainability function is responsible for internal and external stakeholder communication related to sustainability and, together with the Group Accounting function, for sustainability reporting.

The Human Rights Office and Environmental Compliance are also integrated in the Group Sustainability organization. This strengthens close alignment between sustainability strategy, regulatory requirements, and operational implementation. In this context, the Group Sustainability function supports a consistent Group-wide approach to respecting human rights and ensuring environmental compliance, while fostering close cooperation with relevant Group functions and the operating companies.

For further details please refer to our Annual Report 2025.

Question 28

Accepted Answer

Sustainability related performance targets are an integral part of the Compensation System 2023+ for the Management Board members. These reflect our company strategy and enforce our commitment to environmental, social, and governance (ESG) aspects. The ESG targets are integrated into both – short-term and long-term variable compensation.

The non-financial performance targets relevant for the Short-Term Incentive cover the key sustainability topics of medical quality and employees. The Long-Term Incentive includes a CO2 emission reduction target in line with externally communicated company goal of achieving greenhouse gas neutrality in its own operations by 2040.

For further details please refer to our Annual Report 2025.

Question 29

Accepted Answer

Our Sustainability Framework guides our daily actions and shapes how we integrate sustainability into our business.

We focus on three core dimensions:
➔ Human Dimension
➔ Planet Dimension
➔ Ethical Foundation

Please find more information about our sustainability framework in the Sustainability section of our website. Information on the material topics presented in our audited Sustainability Report (according to CSRD) can be found in our Annual Report 2025.

Question 30

Accepted Answer

Leading ESG rating agencies regularly evaluate and review our sustainability performance. An overview of the current ESG ratings is available on our website.

Question 31

Accepted Answer

Our Group Environmental Policy sets out our commitment to sound environmental management practices. It outlines the key elements of our approach and provides an overview of our priorities in environmental protection and applicable minimum standards. These are further specified in Operating Companies-specific documents.

For further information inter alia on the relevance of the topics of climate change, water resources, resource use and circular economy please consult our Annual Report 2025.

Question 32

Accepted Answer

Fresenius has set a climate target for the Group. By 2030, we aim to reduce Scope 1 & 2 emissions in our own operations in absolute value by 50%; by 2040, we want to achieve greenhouse gas neutrality in our own operations (baseline: 2020). We aim to reach net zero along the value chain by 2050.

For further information please refer to our Annual Report 2025.

Question 33

Accepted Answer

Medical care for patients and the well-being of our employees are among the most important engagement areas of our human rights due diligence. Our commitment to respecting human rights is set out in our Group-wide Human Rights Statement.
We rely on highly complex value chains to help ensure that people worldwide have access to healthcare and the medical technology and pharmaceuticals they need. Therefore, our commitment to respecting human rights extends beyond our company and also includes our value chain. We have established the Fresenius Human Rights Program to fulfill our responsibility and meet our due diligence obligations.

Further information on our Human Rights Program is available on our homepage and in our Annual Report 2025.

Question 34

Accepted Answer

Our interactive tool offers a variety of key figures of the Fresenius Group and the business segments. These figures can individually be analyzed and visualized.

Further, we provide a comprehensive overview of metrics in our Sustainability Factbook.

Question 35

Accepted Answer

The Supervisory Board and the Management Board are committed to responsible management that is focused on achieving a sustainable increase in the value of the Company. Long-term corporate strategies, solid financial management, strict adherence to legal and ethical business standards, and transparency in corporate communication are key factors.

Our Corporate Governance Declaration can be found here.

Question 36

Accepted Answer

On May 17, 2023, the Annual General Meeting approved a new compensation system for the members of the Management Board. In particular, the Compensation System 2023+ provides for a new plan for long-term variable compensation that takes even greater account of promoting the long-term and sustainable development of the Company. In addition, the aspect of sustainability has been anchored even more strongly in the long-term variable compensation.

Details on the compensation of the Management Board are available in the AGM invitation 2023.

Question 37

Accepted Answer

On May 21, 2021, the Annual General Meeting approved a new compensation system for the members of the Supervisory Board.

Details on the compensation of the Supervisory Board are available in the AGM invitation 2021.

Question 38

Accepted Answer

An American Depositary Receipt (ADR) is a U.S. dollar denominated negotiable certificate that represents ownership of shares in a non-U.S. company.

Each ADR is issued by a U.S. depositary bank (which is a bank in the United States which oversees all the stock transfer and agency services in connection with a depositary receipt program) and represents one or more shares of a foreign stock or a fraction of a share. If investors own an ADR they have the right to obtain the foreign stock it represents, but U.S. investors usually find it more convenient to own the ADR. The price of an ADR is often close to the price of the foreign stock in its home market, adjusted for the ratio of ADRs to foreign company shares. ADRs were specifically designed to facilitate the purchase, holding and sale of non-U.S. securities by U.S. investors.

Fresenius ADRs represent Fresenius’ local shares deposited with the depositary bank (J.P. Morgan Chase Bank, N.A), to underlie such certificates and carry the rights attached to them as detailed in the Depositary Agreement. Holders of ADRs receive dividends in U.S. dollars and have the right to vote on shareholders resolutions, where applicable.

Question 39

Accepted Answer

An ADR (American Depositary Receipt) is a negotiable certificate issued by a depositary bank representing a specific number of shares of a non-U.S. company traded on a U.S. stock exchange.

An ADS (American Depositary Share) is the share issued under the ADR deposit agreement which is actually traded.

Although the terms ADR and ADS are often used interchangeably, the difference is that an ADR is the certificate while the ADSs are the shares.

Question 40

Accepted Answer

Whereas ADRs allow non-U.S. companies to make their shares available outside their home markets, they also offer a convenient and cost-effective way for U.S. investors to buy shares in non-U.S. companies.

Benefits include:

• Stocks are quoted in U.S dollars
• Dividends are paid in U.S dollars
• ADRs trade during normal U.S trading hours
• ADRs settle and clear according to U.S standards
• No need for custody arrangements outside of the U.S
• Facilitates price comparisons between securities listed in the U.S

Question 41

Accepted Answer

The ADR ratio is the relation between the number of ADRs and the number of local shares. Four Fresenius ADRs represent one Fresenius local share, the ratio is 4:1. The ratio was changed in conjunction with the stock split on August 1, 2014, becoming effective on August 4, 2014. Before that the ADR ratio was 8:1.

Question 42

Accepted Answer

Fresenius ADRs can be purchased like any other stocks, through your U.S. banks and brokers.

Question 43

Accepted Answer

Fresenius ADRs are traded in the U.S. OTC (over-the-counter) market under the ticker FSNUY. The CUSIP Number is 35804M105.

Fresenius ADRs are issued by the depositary bank, JPMorgan. The underlying ordinary shares are deposited by a local custodian bank, usually by a broker who has purchased the ordinary shares in the open market. Once issued, Fresenius ADRs may be traded in the U.S in the OTC market.

When the ADR holder sells, the ADR can either be sold to another investor in the U.S market or cancelled. In the latter case, the ADR is surrendered to the depositary, and the ordinary shares held with the depositary’s custodian would be released back into the home market (i.e. Germany). A Fresenius ADR holder is able to request delivery of the underlying Fresenius Ordinary Shares at any time.

Question 44

Accepted Answer

The OTC market is the market for over-the-counter securities in the United States. This is where sponsored Level I ADR programs are traded. You can refer to www.otcmarkets.com and www.adr.com.

Question 45

Accepted Answer

ADR holders will receive the dividend in U.S. dollars. The depositary bank typically announces the final ADR dividend rate following currency conversion into U.S. dollars. ADR rates and pay dates will be published on www.adr.com.

Question 46

Accepted Answer

Financial and stock information is available in our Share Price tool and in our Interactive Tool.

Trading information is readily available on our depositary bank’s website on www.adr.com/drprofile/35804M105 and on the website of OTC Markets on www.otcmarkets.com/stock/FSNUY/overview.

Question 47

Accepted Answer

Fresenius’ ADR program is administered by J.P. Morgan Chase Bank, N.A. As the depositary bank, J.P. Morgan Chase Bank, N.A performs the following roles for ADR holders as further detailed in the Deposit Agreement:

Records and maintains the register of ADR holders
Is the stock transfer agent
Distributes dividends in U.S. dollars
Facilitates the voting process and the exercise of the voting rights of ADR holders at any Company General Meeting if permitted by the Company and the Depositary Agreement
Issues and cancels Fresenius American Depositary Receipts (ADRs)
Can distribute Company circulars and General Meetings (including Annual General Meeting) documentation, if applicable.

For those holders who are not registered because their ADRs are held through a ‘Street name’ (nominee account), your nominee will receive company documents from time to time from J.P. Morgan Chase Bank, N.A to distribute to ADR holders. You need to make arrangements with your nominee if you wish to receive such documents and to be able to exercise your vote through the depositary bank at General Meetings (if applicable).

Question 48

Accepted Answer

If you do not hold via a broker, bank or nominee, please contact our ADR Transfer Agent, Computershare Trust Company, N.A:

Computershare Trust Company, N.A
General: + +1 888-697-8018
From outside the US: +1-781-575-2844
Email: web.queries@computershare.com
Website: www.computershare.com/investor

For regular correspondence:
Computershare Trust Company, N.A.
P.O. Box 43304
Providence, RI 02940-3304, USA

For delivery of stock certificates & overnight mail:
Computershare Trust Company, N.A
150 Royall Street Canton, MA 02021

https://adr.com/contact/jpmorgan

Question 49

Accepted Answer

Converting ordinary shares into ADRs must be done through a broker or through J.P. Morgan Chase Bank, N.A. You can contact J.P. Morgan Chase Bank, N.A. broker services desk on +1 212 552 8926 or drx_depo@jpmorgan.com.

Question 50

Accepted Answer

If you do not hold via a broker, bank or nominee, please contact our ADR Transfer Agent, Computershare Trust Company N.A:

Computershare Trust Company, N.A
General: + 1 888-697-8018
From outside the US: +1-781-575-2844
Email: web.queries@computershare.com
Website: www.computershare.com/investor

For regular correspondence:
Computershare Trust Company, N.A
P.O. Box 44304
Providence, RI 02940- 3304, USA

For delivery of stock certificates & overnight mail:
Computershare Trust Company, N.A
150 Royall Street Canton, MA 02021

https://adr.com/contact/jpmorgan

Question 51

Accepted Answer

Yes. Certificates can be combined by contacting our Transfer Agent, Computershare:

Computershare Trust Company, N.A
+ 1 888-697-8018
Website: www.computershare.com/investor

For regular correspondence:

Computershare Trust Company, N.A
P.O. Box 44304
Providence, RI 02940-3304, USA

Question 52

Accepted Answer

Stay informed about the latest news and developments at our Group by subscribing to our Investor News and/or to the Fresenius Brief News. These services are free of charge and may be cancelled at any time. Our Information & Order Service is available here. Please scroll fully down this page.

Question 53

Accepted Answer

Our interactive tool offers a variety of key figures of the Fresenius Group and the business segments on an annual and quarterly basis. These figures can individually be analyzed and visualized.

FAQ